Subscribe To
GILD / Gilead (GILD) Exercises Option to License Nurix's Candidate
GILD News
By Business Wire
November 3, 2023
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the America more_horizontal
By Zacks Investment Research
October 30, 2023
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day. more_horizontal
By Zacks Investment Research
October 30, 2023
Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 resul more_horizontal
By Zacks Investment Research
October 24, 2023
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close. more_horizontal
By InvestorPlace
October 20, 2023
7 Healthcare Stocks to invest in for a Healthy Future
One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant develop more_horizontal
By Zacks Investment Research
October 19, 2023
GILD or VRTX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). Bu more_horizontal
By Market Watch
October 17, 2023
Gilead to pay Assembly Bio an initial $100 million as part of 12-year partnership to develop antiviral drugs
Gilead Sciences Inc. GILD, +2.00% announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB, +2.11% to develop antiviral therapies, with more_horizontal
By Seeking Alpha
October 15, 2023
Gilead Sciences Stock Is Cheap, With Broad Pipeline
Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis more_horizontal